Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Evidence-Based Approaches to Choosing the Right Treatment for Bipolar Depression

Source: Recent Advances in the Management of Bipolar Depression
Roger McIntyre, MD, FRCPC, and Sanjay J. Mathew, MD, discuss evidence-based approaches to choosing the right treatment for bipolar depression.
Sanjay J. Mathew, MD
Roger McIntyre, MD, FRCPC
Released: November 30, 2021

In this episode, Roger McIntyre, MD, FRCPC, and Sanjay Mathew, MD, discuss choosing the right treatment in bipolar depression. They review patient assessment and differential diagnosis for bipolar depression, describe various screening tools, examine evidence-based pharmacotherapies, consider the role of adjunctive antidepressants, neuromodulation, light therapy, and psychological treatments, and explore future directions in bipolar depression treatment. 

Information on this Educational Activity

Faculty

Sanjay J. Mathew, MD

Professor and Vice Chair for Research
Psychiatry and Behavioral Sciences
Baylor College of Medicine
Houston, Texas

Sanjay J. Mathew, MD, has disclosed that he has received consulting fees from Clexio, Engrail, Janssen, Neurocrine, Perception Neurosciences, Praxis Precision Medicines, Relmada, and Sage.
Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Roger McIntyre, MD, FRCPC, has disclosed that he has received consulting fees from AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, and Takeda and serves as CEO of Braxia Scientific Corp.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Intra-Cellular Therapies

Related Content

Dr John M. Kane presents advances in treating tardive dyskinesia, from Clinical Care Options (CCO)

John M. Kane, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credit Released: January 20, 2022 Expired: January 19, 2023

Dr John M. Kane presents an expert’s guide to tardive dyskinesia, from Clinical Care Options (CCO)

John M. Kane, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Physician Assistants: maximum of 0.75 hours of AAPA Category I CME credit Released: January 12, 2022 Expired: January 11, 2023

Dr. Greg Mattingly reviews recent advances in treating schizophrenia, from Clinical Care Options (CCO)

Greg Mattingly, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physician Assistants: maximum of 1.0 hour of AAPA Category I CME credit Social Workers: 1.0 ACE CE Credit Psychologists: 1.0 APA CE Credit Released: January 11, 2022 Expired: January 10, 2023

Podcast with Diana Perkins, MD, MPH, and Martha Sajatovic, MD, on the functional and social impact of tardive dyskinesia on the lives of patients, from Clinical Care Options (CCO)

person default Diana O. Perkins, MD, MPH person default Martha Sajatovic, MD Released: January 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings